U.S. regulators on Friday approved AbbVie’s new multidrug regimen for hepatitis C, and the company priced it below rival treatments from Gilead Sciences.
WSJ.com: US Business, Wall Street Journal: Business
Fri, 12/19/2014 - 4:27pm
U.S. regulators on Friday approved AbbVie’s new multidrug regimen for hepatitis C, and the company priced it below rival treatments from Gilead Sciences.